Program
ARM011
A development code.
Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma, led by TriArm Therapeutics (Taiwan).
Furthest: phase 1, since Jul 4, 20251 company-led study, 1 open or runningNext primary completion: Apr 1, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TriArm Therapeutics (Taiwan) | 11 open or running | phase 1since Jul 4, 2025 | Jul 4, 2025 | Apr 1, 2028phase 1 · NCT07066397 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 4, 2025First study: phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaFirst studyNCT07066397 · 12 planned · Taiwan
Ahead
- Apr 1, 2028Primary completion: phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT07066397
TargetBeta
CD19 →read by rule
“ARM011 is an autologous, CD19 targeted CAR T-cell product developed on fast-in-time (FIT) platform-a non-viral, 2-day rapid manufacturing process”study text, by rule · the study
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07066397Precursor Cell Lymphoblastic Leukemia-Lymphoma · Taiwan | 1 | Recruiting | Apr 1, 2028 | 12 |
How it is read
Names in the registry
- “ARM011”, 1 entry
Codes read as this program: ARM011.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.